METACRINE : UPDATES IBD CLINICAL DEVELOPMENT STRATEGY AND IM

METACRINE UPDATES IBD CLINICAL DEVELOPMENT STRATEGY AND IMPLEMENTS RESTRUCTURING PLAN


- U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitis


... | February 11, 2022

Related Keywords

Preston Klassen , Exchange Commission , Drug Administration , Metacrine Inc , Nasdaq , Private Securities Litigation Reform Act , Quarterly Report , Metacrine , Nc Stock Exchange , News , Information , Press Release , Updates , Bd , Linical , Development , Strategy , End , Implements , Restructuring , Fda , Clears , O , Valuate , Et642 , Or , The , Treatment , F , Lcerative Mtcr Us59101e1038 ,